Effect of Erythropoietin Stimulating Agents on Cardiovascular Events in Chronic Kidney Disease Patients on Hemodialysis

  • Ali Asad Khan King Edward Medical University
  • Somia Iqtadar
  • Yasir Shafi
  • Sajid Abaidullah
  • Aasma Refai


Objectives:  Patients with chronic kidney disease (CKD) develop anemia which is treated with erythropoietin-stimulating agents (ESAs). However, ESAs do not reduce the risk of cardiovascular mortality. Furthermore, this is unclear whether ESAs therapy has any association with adverse cardiovascular events.Methods:  After an informed consent 275 male and female patients, between ages 35 to 75 years, with CKD stage V on ESAs undergoing twice weekly hemodialysis were enrolled. The dose of ESAs was calculated according to weight as 50mg/kg with target hemoglobin being 11 – 12 g/dl. Dose adjustments were made in the patients who failed to achieve target hemoglobin. The patients were followed for a year with the primary end point being new evidence of acute myocardial infarction (MI) diagnosed through ECG or echocardiography. Safety outcomes included stroke or death.Results:  The data was entered and analyzed in Statistical Package for Social Sciences (SPSS) version 18Out of 275 patients, 164 (59.6%) patients were males and 111 (40.4%) were females. Mean age of the patients was 51.52 with standard deviation of ± 5.73. According to the results, 52 (18.9%) patients reported with MI and 223 (81.1%) patients had no evidence of MI. Out of 52 patients who had MI, 37 (71.1%) were males and 15 (28.8%) patients were female.Conclusion:  ESAs are associated with an increased risk of MI in CKD patients on hemodialysis. Whether there is a direct association or there are other factors involved remains to be seen.
How to Cite
KHAN, Ali Asad et al. Effect of Erythropoietin Stimulating Agents on Cardiovascular Events in Chronic Kidney Disease Patients on Hemodialysis. Annals of King Edward Medical University, [S.l.], v. 23, n. 2, june 2017. ISSN 2079-0694. Available at: <http://www.annalskemu.org/journal/index.php/annals/article/view/1577>. Date accessed: 26 apr. 2018. doi: https://doi.org/10.21649/akemu.v23i2.1577.


Chronic Kidney Disease, Erythropoietin stimulating agents, Myocardial Infarction, Anemia

Most read articles by the same author(s)

1 2 > >>